Leprosy Clinical Trial - Bedaquiline Enhanced Post ExpOsure Prophylaxis

Status Completed

Clinical Trial Summary

This study will evaluate a combination of bedaquiline and rifampicin as post exposure prophylaxis (PEP) for leprosy in Comoros. It will be a follow-up to the PEOPLE trial on PEP with rifampicin, which is ending in 2022. This new trial will be called the 'Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy' or 'BE-PEOPLE' trial. There will be two main study arms, a comparator arm based on the current WHO recommendation of providing a single dose of rifampicin (10 mg/kg) to close contacts of leprosy patients and an intervention arm in which this regimen will be reinforced with bedaquiline, 400 or 800 mg depending on weight, to be repeated once after four weeks for household contacts. The main study will be preceded by a phase 2 safety study.

Clinical Trial Description

Given the fact that the investigators are going to provide to healthy people a drug that has not been used before for this indication and which has only been conditionally approved for use in multi-drug resistant tuberculosis, they have first foreseen a phase 2 study in which BE-PEP will be provided to a limited number of contacts and in which safety will be closely monitored and evaluated by an independent data and safety monitoring board (DSMB). This will be done in a small village that is part arm 1 of the PEOPLE trial in which 8 new cases have been diagnosed since 2019 but no PEP has been provided. The investigators will conduct door-to-door screening in this village in June 2022 and offer a single dose of BE-PEP to a random sample of 150 people screened aged 5 years and above not meeting the exclusion criteria (active tuberculosis (TB) or leprosy or previously treated leprosy, known liver function or cardiac abnormalities, not able to swallow 100 mg bedaquiline tablets). Participants will be followed up closely with active monitoring for adverse events, including measurement of the corrected QT interval and liver function before and after administration, as well as gastro-intestinal (nausea, vomiting), nervous system-related (headache, dizziness) and cutaneous reactions. The remainder of the population of this village aged two years and above will be offered single dose rifampicin as per WHO recommendations. In a randomly sampled subset of 150 individuals receiving rifampicin only, the same stringent monitoring with ECG and liver function tests also applied in those receiving BE-PEP will be performed. ;

Study Design

Related Conditions & MeSH terms

Leprosy

Clinical Trial Details

NCT number	NCT05406479
Study type	Interventional
Source	Institute of Tropical Medicine, Belgium
Contact
Status	Completed
Phase	Phase 2
Start date	July 14, 2022
Completion date	January 26, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03302897` - Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers	Phase 1
Recruiting	`NCT05243654` - Efficacy and Tolerability of Adjunct Metformin for Multibacillary Leprosy	Phase 2
Completed	`NCT05091216` - The Effects of Traditional Chinese Medicine Mouthwash Solutions on the Oral Health of Leprosy Patients	N/A
Completed	`NCT00860717` - The Use of Low Level Laser Therapy for Wound Healing in Leprosy Patients	N/A
Recruiting	`NCT06222372` - Novel Interventions and Diagnostic Tests for Leprosy	N/A
Terminated	`NCT03084614` - CD8 Reactivity to Microorganisms in Blood and Breast Milk
Recruiting	`NCT05597280` - Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy	Phase 3
Terminated	`NCT01751503` - Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer	N/A
Active, not recruiting	`NCT03324035` - Treatment of Neuropathic Pain in Leprosy	Phase 3
Completed	`NCT03683745` - Integrated Mapping of Skin-presenting Neglected Tropical Diseases in Liberia
Recruiting	`NCT02550080` - Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome	Phase 4
Completed	`NCT02484469` - Impact of the Virtual Human Project on Team-based Learning: A Randomized-controlled Trial	N/A
Completed	`NCT00919542` - Ciclosporin in the Management of New Erythema Nodosum Leprosum	Phase 2
Completed	`NCT01165840` - Effect of Weight and/or Obesity on Dapsone Drug Concentrations	Phase 4
Recruiting	`NCT03807362` - CC-11050 Trial in Nepalese Patients With Erythema Nodosum Leprosum	Phase 2
Completed	`NCT01006759` - Prevention of Disability: Proposal for a Guidance Manual for Leprosy Patients	Phase 1
Completed	`NCT03662022` - Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar	Phase 3
Completed	`NCT01920750` - Leprosy Skin Test Antigens Phase 1	Phase 1
Recruiting	`NCT06416033` - Serum Irisin Level In Leprosy Patients
Not yet recruiting	`NCT03947437` - Phase 1b/2a Trial to Evaluate LEP-F1 + GLA-SE in Healthy Adults and Leprosy Patients	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2) — BE-PEOPLE P2

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms